A Phase 1 Double Blind (3rd Party Open) Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Repeat Doses Of Pf-06743649 In Healthy Elderly Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2016
Price : $35 *
At a glance
- Drugs PF 6743649 (Primary)
- Indications Gout
- Focus Pharmacokinetics
- Sponsors Pfizer
- 11 Feb 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 24 Nov 2014 Planned End Date changed from 1 Dec 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
- 11 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.